Abstract
Objectives The emergence of new SARS-CoV-2 variants is a major challenge in the management of Covid-19 pandemic. A crucial issue is to quantify the number of variants which may represent a potential risk for public health in the future.
Methods We fitted the data on the most relevant SARS-CoV-2 variants recorded by the World Health Organization (WHO). The function exploited for the fit is related to the total number of infected subjects in the world since the start of the epidemic.
Results We found that the number of new relevant variants per ten million cases diminished by 30.4% between March 2020 and March 2022 (from 1.25 to 0.87). However, the decrease is now very slow and a further reduction by 10% would happen only for 5.6 billion infections in the world, i.e. ten times the cases from the beginning of the epidemic up to June 2022.
Conclusion Our simple mathematical model can provide an estimate of the number of relevant SARS-CoV-2 variants as the cumulative number of cases increases worldwide and may represent a useful tool in planning strategies to effectively contrast the pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the "Fondazione di Sardegna" (Grant n. 2022-0209). The funders had no role in study design, data analysis, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://www.who.int/en/activities/tracking-SARS-CoV-2-variants
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail addresses: roby.litter{at}gmail.com (R. Littera).
Update of the SARS-CoV-2 variants and fit of the new WHO data. Revision and integration of text, figures and tables. New Appendix on the fit of ECDC data.
Data Availability
All data referred to in the manuscript are available online at https://www.who.int/en/activities/tracking-SARS-CoV-2-variants
